In vivo antitumor activity of IL-15–producing CAR NK cells. (A) Experimental scheme of the in vivo evaluation of a single dose of IL-15–producing CAR NK cells in a Jeko-1-CD19KO-CBG-BFP xenograft model. (B) Bioluminescent imaging analysis in Jeko-1-CD19KO-CBG-BFP tumor–bearing mice after the infusion of indicated CAR NK cells (n = 5). (C) The average radiance measured over the course of 63 days as an indication for Jeko-1-CD19KO-CBG-BFP tumor growth in vivo. (D) Kaplan-Meier plots showing the survival of tumor-bearing mice treated with the indicated CAR NK cells. MS, median survival. ∗∗P < .01, ∗∗∗P < .001, and ∗∗∗∗P < .0001. P values were determined by 2-way ANOVA and log-rank test. (E) Bioluminescent imaging analysis in Raji-CD19KO-CBRluc-BFP tumor–bearing mice after the infusion of indicated CAR NK cells (n = 5). (F) The average radiance measured over the course of 44 days as an indication for Raji-CD19KO-CBRluc-BFP tumor growth in vivo. (G) Kaplan-Meier plots showing survival of tumor bearing mice treated with the indicated CAR NK cells. ∗P < .05, ∗∗P < .01, and ∗∗∗∗P < .0001. P values were from 2-way ANOVA and log-rank test.